Technology | November 20, 2008

New Molecular CT Adds Metabolic Information from PET

Siemens Healthcare said its new molecular CT is designed to provide a premium-imaging platform and is a practical solution for today’s shrinking healthcare budget.

The new technology, Biograph mCT, combines a CT with molecular capabilities, a PET scanner with unlimited capabilities in CT and a high performance integrated imager that can be used to achieve true collaboration and cooperation between diagnostic imaging specialties, according to the company.

Biograph mCT is designed to obtain functional, anatomical and molecular information from one, noninvasive diagnostic exam, and aims to adapt to virtually any patient and any clinical need with higher resolution, contrast and speed. The clinician has the option of using CT in conjunction with the high-definition PET technology or as a standalone CT. Depending on the case, molecular contrast can be used for additional metabolic information. Biograph mCT is reportedly the only imaging device to offer whole-body PET-CT scanning in just five minutes.

With a small footprint, large bore, a short tunnel and an extra-wide, 500-pound-capacity bed (227 kg), Biograph mCT is designed to accommodate all kinds of patients -- including pediatric, bariatric and geriatric -- comfortably and easily. Biograph mCT’s large 78 cm bore can also help to alleviate patients’ sense of claustrophobia and allows better positioning of RTP devices, such as breast boards, and makes scanning of obese patients easier.

Biograph mCT adapts to virtually all patient types and clinical needs. Its sotropic resolution in CT brings out the finest anatomical details in every scan -- routine and advanced -- limiting motion artifacts. It is available in detector configurations of 40-, 64-, and 128-slices, a first in integrated scanners. Biograph mCT’s HD-PET technology delivers detailed images with up to four times as much contrast. It is reportedly the only PET technology that offers 2 mm uniform resolution throughout the field of view (FOV).

Biograph mCT also addresses two of the foremost concerns related to scanning: scan time and radiation dose. With its ultra-low dose capability and super-fast PET acquisition time, scanning can be less stressful for the clinician and the patient, according to Siemens.

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init